Associate editor: B. TeicherNew targets and approaches in osteosarcoma
Introduction
Osteosarcoma (OS) is the most common primary malignant tumor arising from bone in children and young adults. It arises from mesenchymal cells and is pathologically characterized by spindle cells and aberrant osteoid formation. The incidence of OS has a bimodal distribution with a peak in adolescence and a second peak occurring in the seventh and eighth decade of life. The latter peak, in the era prior to the advent of bisphosphonates, likely represents a consequence of long-standing Paget's disease of bone (Mirabello et al., 2009). In children and young adults, approximately 400 new cases of OS are diagnosed in the United States each year, making it the eighth most common malignancy of childhood (Ottaviani & Jaffe, 2009).
High-grade OS can occur in any bone. Most commonly, OS originates juxtaposed to the knee joint involving the distal femur (43%) or proximal tibia (23%). The proximal humerus, the next most common site of disease, represents approximately 10% of cases (Bielack et al., 2002). These bones experience rapid cell division to facilitate the increased growth velocity during adolescence. Within the bone, OS typically occurs in the metaphysis in proximity to the growth plate. The stimulatory signals associated with pubertal growth may represent an inciting event in the oncogenesis of OS.
Most patients with newly diagnosed OS present with localized disease. Approximately 15–20% of patients have metastases detectable at presentation. The lung is the most common site of metastasis, comprising more than 85% of metastatic disease, with bone being the second most common site of distant disease (Bielack et al., 2002). However, these data are limited by the technology available to detect metastatic disease. Prior to the era of modern chemotherapy, greater than 80% of patients with localized disease treated by amputation alone developed metastases, most occurring within one year of diagnosis (Marcove et al., 1970). Given this experience, it is considered that most patients with localized OS have micrometastases at presentation.
The curative approach to OS entails both surgery and chemotherapy. The benefit of chemotherapy has been validated by Multi-Institutional Osteosarcoma Study (MIOS) conducted in the 1980's, in which patients were randomized to surgery alone versus adjuvant chemotherapy following amputation for localized OS. The patients randomized to receive chemotherapy had a significant improvement in their 2-year relapse-free survival: 66 versus 17% (Link et al., 1986). This significant difference persisted at follow-up greater than 5-years, validating that the addition of chemotherapy improves overall survival and does not just delay time to progression.
Chemotherapy for osteosarcoma is administered in both the neoadjuvant and adjuvant setting. The rationale for preoperative chemotherapy originated in the late 1970's in centers, accustomed to using chemotherapy for osteosarcoma, looking to avoid amputation. Preoperative chemotherapy provided a necessary bridge until a custom-fitted prosthesis could be constructed, which in the initial protocols required several months (Rosen et al., 1979). Despite improvements in manufacturing, this legacy has persisted, and most protocols today mandate 10–12 weeks of preoperative chemotherapy before proceeding to definitive resection. A randomized trial comparing neoadjuvant chemotherapy to surgery followed by adjuvant chemotherapy found that immediate surgery provided no benefit over delayed surgery (Goorin et al., 2003).
Another legacy of neoadjuvant chemotherapy is the ability to measure the chemoresponsiveness of a patient's tumor by evaluating the degree of tumor necrosis. This was initially codified into the Huvos grading system, ranging from grade I (little or no effect identified) to grade IV (no histologic evidence of viable tumor identified within the entire specimen) (Rosen et al., 1983). This has been further modified into the tumor necrosis grading which reports the percent necrosis within the resected tumor. The degree of tumor necrosis following neoadjuvant chemotherapy has been shown to be predictive of overall survival. Patients with Huvos grade III or IV, corresponding to greater than 90% necrosis, are generally considered good responders. Patients with a good response to chemotherapy have a disease-free survival greater than 65%. Some studies have demonstrated that patients with a grade IV response to chemotherapy have markedly better outcomes than patients with a grade III response. In comparison, the poor-responders' disease-free survival approaches 50% (Bacci et al., 2005). The tumor necrosis grade can thus be used as a surrogate marker for the chemoresponsiveness of the individual's tumor to neoadjuvant chemotherapy.
Investigators attempting to identify new agents or combination regimens have used this tool to extrapolate differences in tumor necrosis to effects on survival. To that effect, it has been demonstrated that increasing the number of agents in the neoadjuavant period increases the percentage of patients with higher grades of necrosis (Bacci et al., 2003). Likewise, it has been shown that increasing the duration of preoperative chemotherapy increases the percentage of patients with higher grades of necrosis. However, the predictive value of tumor necrosis grade on overall survival is blunted by the intensification of preoperative chemotherapy (Meyers et al., 1998). Hence, the use of the preoperative window period to test the anti-tumor activity of new agents has to be done with caution as those results may not reflect an anti-cancer effect leading to improvement in survival, but may be more reflective of the innate biology of the individual's tumor. Likewise, some biomarkers have been shown to correlate with survival but not with histologic response. A case in point is the biomarker, p-glycoprotein, the protein product of the multidrug resistance gene MDR1¸which functions as an ATP dependent efflux pump. In a meta-analysis, p-glycoprotein expression nearly doubles the risk of progression at 2 years, but had a sensitivity and specificity approaching 50% for histologic response (Pakos & Ioannidis, 2003). This discordance highlights the difficulty of using the grade of tumor necrosis as a surrogate marker for overall survival. To date, no molecular markers have been prospectively validated to predict response to chemotherapy and overall survival. For patients with poor response to neoadjuvant chemotherapy, no markers have been validated to help delineate patients who are likely to be cured with the current chemotherapeutic regimens or those who may benefit from investigational or escalation of therapy.
Section snippets
Conventional chemotherapy
Historically, many agents have been tried by clinicians attempting to improve the outcome of patients with OS. Since the 1990's many protocols have contained a similar three-drug backbone consisting of methotrexate, doxorubicin, and cisplatin (MAP), which are considered active agents in OS, with the possible inclusion of ifosfamide and etoposide (Table 1).
Methotrexate has been used to treat osteosarcoma since the early 1970's (Jaffe, 1972). Methotrexate is an analog of folic acid. Its
Investigational agents
In addition to traditional chemotherapy, there are multiple investigational agents being studied which target pathways that are believed to be active in OS (Fig. 1, Table 2).
Conclusion
The majority of patients with osteosarcoma are cured with the current treatment strategies. However, approximately 1/3 of patients will relapse of which only a minority will not ultimately succumb from their disease. In the treatment of osteosarcoma, four agents have been demonstrated to have proven activity: methotrexate, doxorubicin, cisplatin, and ifosfamide. Combination regimens using three of these agents have demonstrated similar results. However, several trials have demonstrated that
References (107)
- et al.
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
Eur J Cancer
(2011) - et al.
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol
Eur J Cancer
(2001) - et al.
Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution
Eur J Cancer
(2005) - et al.
153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients
Ann Oncol
(2012) - et al.
Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature
Cancer Genet Cytogenet
(1997) - et al.
A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma
Eur J Cancer
(2012) - et al.
Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis
Neoplasia
(2007) - et al.
Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology
Eur J Cancer
(1997) - et al.
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Ann Oncol
(2012) - et al.
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
Clin Breast Cancer
(2011)
Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma
Mod Pathol
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma
J Thorac Oncol
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients
Eur J Cancer
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Lancet Oncol
A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
Eur J Cancer
Pemetrexed: a multitargeted antifolate
Clin Ther
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Lancet Oncol
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Cell
Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome
Pathology
A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate
Eur J Cancer
The Aurora kinase family in cell division and cancer
Biochim Biophys Acta
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
Cancer
Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases
Clin Cancer Res
Activity of SCH717454 in Subjects with Relapsed Osteosarcoma or Ewing's Sarcoma
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group
Clin Cancer Res
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
J Clin Oncol
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome
J Pediatr Hematol Oncol
Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors
Clin Cancer Res
Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells
J Cell Sci
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
J Clin Oncol
Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines
Pediatr Blood Cancer
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study
Pediatr Blood Cancer
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone
Clin Cancer Res
Growth inhibition of human osteosarcomas in nude mice by human interferon-alpha: significance of dose and tumor differentiation
Cancer Res
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
J Clin Oncol
Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines
Pediatr Blood Cancer
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group
Cancer
Doxorubicin in disseminated osteosarcoma
JAMA
Amputation and adriamycin in primary osteosarcoma
N Engl J Med
Zoledronic acid inhibits osteosarcoma growth in an orthotopic model
Mol Cancer Ther
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial
Cancer
Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin
J Med Chem
p53 functions as a cell cycle control protein in osteosarcomas
Mol Cell Biol
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
Proc Natl Acad Sci U S A
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group
J Clin Oncol
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit
Oncogene
Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups
J Clin Oncol
Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide
Proc Natl Acad Sci U S A
Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Anticancer Res
Cited by (255)
Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma
2024, Journal of Bone OncologyMultifunctional nanoparticles for the treatment and diagnosis of osteosarcoma
2023, Biomaterials AdvancesTargeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer
2022, Journal of Bone Oncology